Brief: 4Dmt To Present Interim Data From Phase 1/2 Prism Clinical Trial For Wet AMD At Arvo 2023
13/04/2023 14:00
April 13 (Reuters) - 4D Molecular Therapeutics Inc
FDMT.O :
* 4DMT TO PRESENT INTERIM DATA FROM 4D-150 PHASE 1/2 PRISM
CLINICAL TRIAL FOR WET AMD AT ARVO 2023, AND PROMOTES ROBERT
KIM, M.D. TO CHIEF MEDICAL OFFICER
Source text for Eikon: ID:nGNX4cmBSt
Further company coverage: FDMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings